Clinical Trial Search

Primary: Radiographic Progression-free Survival (rPFS) Per Prostate Cancer Working Group (PCWG)-Modified Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as…

Primary: % of Subjects With Treatment Response — 42; 34; 30; 20 Participants — p=0.034

Primary: IgG Trough Levels From Baseline to End of Study (28 Weeks) — 0.144; 0.065; -0.593 g/L

Primary: Number of Fertilized (2 Pronuclei [2PN]) Oocytes — 8.3; 6.7 Fertilized oocytes

Primary: Change From Baseline in the HAMD-17 Total Score at Day 3 — -7.0; -8.9 score on a scale — p=0.0004

Primary: Lean Squares Mean (± Standard Error) of Math Test Score Over All Post-dose Time Points (0.5, 1, 2, 4, 8, 10, 12, 13, and 14 Hours Post-dose) Assessed During the…

Primary: Change From Baseline in Scratching Score — -1.69; -0.8 score on a scale — p=0.0012

Primary: Changes in Forced Expiratory Volume in One-second (FEV1) Slope in Milliliters Per Month — 1; -12 milliliters per month — p=<0.001

Primary: Percentage of Participants Who Reach Complete Amyloid Plaque Clearance on Florbetapir F18 Positron Emission Tomography (PET) Scan (Superiority) on Donanemab Versus…

Primary: Change From Baseline in Hemoglobin A1c (HbA1c) (Pooled Doses of Tirzepatide 5 mg, 10 mg and 15 mg) — -2.26; -1.16 Percentage of HbA1c — p=<0.001

Primary: OS in Participants With Left-sided Tumors — 37.85; 34.30 Months

Primary: Progression-free Survival (PFS) — 4.5; 4.0 Months — p=0.4107

Primary: Percentage of Participants With Active Disease at Baseline Who Achieved Normalization of Serum Albumin and Improvement in Prespecified Clinical Outcomes at Week 24 — 100…

Primary: Percentage of Participants Reporting Local Reactions Within 7 Days After Vaccination With RSVpreF or Placebo — 10.1; 6.5; 7.6; 11.5 Percentage of participants

Primary: Proportion of Subjects With Successful Bowel Preparation — 212; 211 Participants — p=<0.001